JP2019501957A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501957A5 JP2019501957A5 JP2018543455A JP2018543455A JP2019501957A5 JP 2019501957 A5 JP2019501957 A5 JP 2019501957A5 JP 2018543455 A JP2018543455 A JP 2018543455A JP 2018543455 A JP2018543455 A JP 2018543455A JP 2019501957 A5 JP2019501957 A5 JP 2019501957A5
- Authority
- JP
- Japan
- Prior art keywords
- pdgf
- seq
- amino acids
- breast cancer
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 10
- 239000000328 estrogen antagonist Substances 0.000 claims 9
- 229940000425 combination drug Drugs 0.000 claims 8
- 206010006187 Breast cancer Diseases 0.000 claims 7
- 208000026310 Breast neoplasm Diseases 0.000 claims 7
- 108091008606 PDGF receptors Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960004622 raloxifene Drugs 0.000 claims 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- DUDKAZCAISNGQN-UHFFFAOYSA-N Oxyphencyclimine Chemical compound CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 DUDKAZCAISNGQN-UHFFFAOYSA-N 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 229960003437 aminoglutethimide Drugs 0.000 claims 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 208000010572 basal-like breast carcinoma Diseases 0.000 claims 1
- -1 borozole Chemical compound 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 229950011548 fadrozole Drugs 0.000 claims 1
- 229960004421 formestane Drugs 0.000 claims 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical group C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960002369 oxyphencyclimine Drugs 0.000 claims 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 229960005026 toremifene Drugs 0.000 claims 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022011194A JP2022058781A (ja) | 2015-11-10 | 2022-01-27 | Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1551455 | 2015-11-10 | ||
| SE1551455-7 | 2015-11-10 | ||
| SE1650974-7 | 2016-07-04 | ||
| SE1650974 | 2016-07-04 | ||
| PCT/EP2016/077295 WO2017081171A1 (en) | 2015-11-10 | 2016-11-10 | Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022011194A Division JP2022058781A (ja) | 2015-11-10 | 2022-01-27 | Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501957A JP2019501957A (ja) | 2019-01-24 |
| JP2019501957A5 true JP2019501957A5 (enExample) | 2019-12-19 |
| JP7048505B2 JP7048505B2 (ja) | 2022-04-05 |
Family
ID=57321296
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543455A Active JP7048505B2 (ja) | 2015-11-10 | 2016-11-10 | Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 |
| JP2022011194A Pending JP2022058781A (ja) | 2015-11-10 | 2022-01-27 | Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022011194A Pending JP2022058781A (ja) | 2015-11-10 | 2022-01-27 | Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11633382B2 (enExample) |
| EP (1) | EP3373967B9 (enExample) |
| JP (2) | JP7048505B2 (enExample) |
| CN (1) | CN108348605B (enExample) |
| AU (1) | AU2016352592B2 (enExample) |
| WO (1) | WO2017081171A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3666276A1 (en) * | 2018-12-14 | 2020-06-17 | dcic Biopharmaceutical Limited | Medication against estrogen-receptor beta (erbeta) positive breast tumor |
| BR112022020322A2 (pt) * | 2020-04-10 | 2022-12-13 | Jina Pharmaceuticals Inc | Método para gerenciar ou diminuir um risco de efeitos adversos em um paciente submetido ao tratamento de distúrbio bipolar i |
| WO2022164269A1 (ko) * | 2021-01-29 | 2022-08-04 | 한국과학기술원 | 악성 유방암의 치료 또는 예방용 약학적 조성물 |
| WO2023172891A2 (en) * | 2022-03-07 | 2023-09-14 | Baylor College Of Medicine | Biomarkers for combination therapy for er+ breast cancer |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2464203A (en) | 1943-05-21 | 1949-03-15 | Boots Pure Drug Co Ltd | Manufacture of dienoestrol |
| US2465505A (en) | 1944-12-05 | 1949-03-29 | Hoffmann La Roche | Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4 |
| US2914562A (en) | 1957-08-06 | 1959-11-24 | Wm S Merrell Co | Amine derivatives of triphenylethanol |
| BE637389A (enExample) | 1962-09-13 | |||
| US3822287A (en) | 1969-04-17 | 1974-07-02 | Rexall Drug Chemical | Process for preparation of substituted 3,4-(diphenyl)chromans |
| US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4230862A (en) | 1975-10-28 | 1980-10-28 | Eli Lilly And Company | Antifertility compounds |
| DE2658307C2 (de) | 1976-12-22 | 1979-03-15 | Klinge Pharma Gmbh & Co, 8000 Muenchen | Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE2860900D1 (en) | 1977-08-22 | 1981-11-05 | Ici Plc | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them |
| DE3046719C2 (de) | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| US5491173A (en) | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| IE58417B1 (en) | 1984-04-27 | 1993-09-22 | Ici Plc | Chemical derivatives |
| GB8517360D0 (en) | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
| US5352795A (en) | 1986-03-07 | 1994-10-04 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| DE3762617D1 (de) | 1986-09-11 | 1990-06-13 | Nat Res Dev | Tamoxifenderivate. |
| GB8714013D0 (en) | 1987-06-16 | 1987-07-22 | Ici Plc | (substituted-aralkyl)heterocyclic compounds |
| US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| AU665690B2 (en) | 1992-05-08 | 1996-01-11 | Otsuka Pharmaceutical Factory, Inc. | Indole derivative |
| TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| GB9326332D0 (en) | 1993-12-23 | 1994-02-23 | Karo Bio | Indole derivatives |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| DE4426625A1 (de) | 1994-07-27 | 1996-03-14 | Schering Ag | 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| US5726202A (en) | 1996-01-11 | 1998-03-10 | Novo Nordisk A/S | Benign prostatic hypertrophy |
| CA2241623A1 (en) | 1996-01-11 | 1997-07-17 | Novo Nordisk A/S | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms |
| BR9706966A (pt) | 1996-01-11 | 1999-05-04 | Novo Nordisk As | Utilização do enanciômero-l de um composto e processo para tratamento ou profilaxia de câncer da mama |
| US5883118A (en) | 1996-01-11 | 1999-03-16 | Nova Nordisk A/S | Prostatic carcinoma |
| US5880137A (en) | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| US5780497A (en) | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US5985910A (en) | 1996-04-19 | 1999-11-16 | American Home Products Corporation | 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| ZA982818B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Prevention of breast cancer using selective estrogen receptor modulators. |
| ZA982819B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators. |
| ZA982877B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
| ES2239793T3 (es) | 1997-08-07 | 2005-10-01 | Eli Lilly And Company | Compuestos de 1-(4-(alcoxi sustituido)bencil)naftaleno con actividad inhibidora de estrogenos. |
| PE20000129A1 (es) | 1997-12-23 | 2000-03-11 | Schering Ag | 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa |
| US6548491B2 (en) | 1997-12-24 | 2003-04-15 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| US6069153A (en) | 1998-05-12 | 2000-05-30 | American Home Products Corporation | Indenoindoles and benzocarbazoles as estrogenic agents |
| EP1102755B1 (en) | 1998-08-07 | 2006-01-04 | Chiron Corporation | Substituted isoxazole derivatives as estrogen receptor modulators |
| TW593256B (en) | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| US6340774B1 (en) | 2000-01-31 | 2002-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Non-steroidal estrogen-receptor antagonists |
| DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| WO2001098322A1 (en) | 2000-06-22 | 2001-12-27 | Northeastern University | Novel steroidal antiestrogens and antiandrogens and uses thereof |
| US6750213B2 (en) | 2000-10-19 | 2004-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| US6599921B2 (en) | 2001-02-22 | 2003-07-29 | Nanodesign, Inc. | Non-steroidal estrogen receptor ligands |
| JP2005528320A (ja) | 2001-08-11 | 2005-09-22 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | 選択的なエストロゲン受容体モジュレーター |
| WO2003015761A1 (en) | 2001-08-13 | 2003-02-27 | Merck & Co., Inc. | Selective estrogen receptor modulators |
| US7138426B2 (en) | 2002-04-24 | 2006-11-21 | Merck & Co., Inc. | Estrogen receptor modulators |
| WO2005087812A1 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| AR051597A1 (es) | 2004-11-01 | 2007-01-24 | Merck & Co Inc | Moduladores de los receptores de estrogeno |
| EP2021028A2 (en) | 2006-04-17 | 2009-02-11 | Ludwig Institute For Cancer Research | Methods and compositions for modulation of blood-neural barrier |
| WO2008033887A2 (en) * | 2006-09-13 | 2008-03-20 | Nuvelo, Inc. | Methods for treating cancer |
| US7504530B2 (en) | 2007-02-14 | 2009-03-17 | Hormos Medical Ltd. | Methods for the preparation of fispemifene from ospemifene |
| AU2008321128A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| JP2013525296A (ja) | 2010-04-16 | 2013-06-20 | ノバルティス アーゲー | 内分泌療法抵抗性乳癌の処置 |
| CA2871528A1 (en) | 2012-04-24 | 2013-10-31 | Thrombogenics N.V. | Anti-pdgf-c antibodies |
| WO2014070523A1 (en) | 2012-11-02 | 2014-05-08 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
-
2016
- 2016-11-10 US US15/774,341 patent/US11633382B2/en active Active
- 2016-11-10 EP EP16795300.9A patent/EP3373967B9/en active Active
- 2016-11-10 AU AU2016352592A patent/AU2016352592B2/en active Active
- 2016-11-10 WO PCT/EP2016/077295 patent/WO2017081171A1/en not_active Ceased
- 2016-11-10 CN CN201680065636.1A patent/CN108348605B/zh active Active
- 2016-11-10 JP JP2018543455A patent/JP7048505B2/ja active Active
-
2022
- 2022-01-27 JP JP2022011194A patent/JP2022058781A/ja active Pending
-
2023
- 2023-03-14 US US18/121,075 patent/US20230310385A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502120A5 (enExample) | ||
| Bringhen et al. | New agents in multiple myeloma: an examination of safety profiles | |
| EP4509527A3 (en) | Post-translationally modified fully human antibody therapeutic agents | |
| JP2016513640A5 (enExample) | ||
| RU2017140674A (ru) | Способы лечения рака | |
| JP2014525465A5 (enExample) | ||
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| JP2017530983A5 (enExample) | ||
| JP2019501957A5 (enExample) | ||
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| BR112018071585A2 (pt) | formulações de um inibidor de lsd1 | |
| JP2016536286A5 (enExample) | ||
| MX2021001143A (es) | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. | |
| JP2014511383A5 (enExample) | ||
| JP2019532047A5 (enExample) | ||
| JP2017518302A5 (enExample) | ||
| JP2015500887A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| Orlowski | Novel agents for multiple myeloma to overcome resistance in phase III clinical trials | |
| JP2016516074A5 (enExample) | ||
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| JP2017514853A5 (enExample) | ||
| JP2019530706A5 (enExample) | ||
| RU2017116070A (ru) | Способ лечения первичного гормонорезистентного эндометриального рака и рака груди |